One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Bone and Mineral Research

• Publication date

  2009-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1359/jbmr.090215PMID 19257823
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activation of β‐Catenin Signaling in Articular Chondrocytes Leads to Osteoarthritis‐Like Phenotype in Adult β‐Catenin Conditional Activation Mice

  2009cited by this paper
• The Evolving Systemic and Local Biomarker Milieu at Different Stages of Disease Progression in Rat Adjuvant-Induced Arthritis

  2009cited by this paper
• Sclerosing bone disorders.

  2008cited by this paper
• OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST

  2008cited by this paper
• Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

  2008cited by this paper
• Quantitative associations between osteocyte density and biomechanics, microcrack and microstructure in OVX rats vertebral trabeculae.

  2008cited by this paper
• RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized Rats

  2008cited by this paper
• RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.

  2007cited by this paper
• Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses1

  2007cited by this paper
• Differential Bone Metabolism Between Postmenopausal Women With Osteoarthritis and Osteoporosis

  2007cited by this paper
• No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women.

  2007cited by this paper
• The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys

  2007cited by this paper
• Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway.

  2006cited by this paper
• Co‐Treatment of PTH With Osteoprotegerin or Alendronate Increases Its Anabolic Effect on the Skeleton of Oophorectomized Mice

  2006cited by this paper
• Should children with osteogenesis imperfecta be treated with bisphosphonates?

  2006cited by this paper
• RANKL Inhibition: A Novel Strategy to Decrease Femoral Head Deformity After Ischemic Osteonecrosis

  2006cited by this paper
• Denosumab in postmenopausal women with low bone mineral density.

  2006cited by this paper
• RANKL is a Marker and Mediator of Local and Systemic Bone Loss in Two Rat Models of Inflammatory Arthritis

  2005cited by this paper
• The RANKL Inhibitor Osteoprotegerin (OPG) Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared to Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy

  2005cited by this paper
• Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.

  2005cited by this paper
• The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

  2005cited by this paper
• Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

  2005cited by this paper
• Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.

  2005cited by this paper
• Quantification of metaphyseal modeling in children treated with bisphosphonates.

  2005cited by this paper
• Osteoclastogenesis Inhibitory Factor/Osteoprotegerin Reduced Bone Loss Induced by Mechanical Unloading

  2004cited by this paper
• Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study

  2004cited by this paper
• Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading

  2004cited by this paper
• Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in Rats

  2003cited by this paper
• Bisphosphonate-induced osteopetrosis.

  2003cited by this paper
• Serum levels of osteoprotegerin increase with age in a healthy adult population.

  2003cited by this paper
• Age and distance from the surface but not menopause reduce osteocyte density in human cancellous bone.

  2002cited by this paper
• Mechanical properties in long bones of rat osteopetrotic mutations.

  2002cited by this paper
• Localization of Osteoprotegerin (OPG) on Bone Surfaces and Cement Lines in Rat Tibia

  2002cited by this paper
• Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.

  2002cited by this paper
• Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis

  2002cited by this paper
• The effects of osteoprotegerin on the mechanical properties of rat bone

  2001cited by this paper
• Expression Profiles of Receptor Activator of Nuclear Factor κB Ligand, Receptor Activator of Nuclear Factor κB, and Osteoprotegerin Messenger RNA in Aged and Ovariectomized Rat Bones

  2001cited by this paper
• Mineral Density and Bone Strength Are Dissociated in Long Bones of Rat Osteopetrotic Mutations

  2000cited by this paper
• Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.

  2000cited by this paper
• RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

  2000cited by this paper
• Osteoprotegerin mitigates tail suspension-induced osteopenia.

  2000cited by this paper
• RANK is essential for osteoclast and lymph node development.

  1999cited by this paper
• Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors

  1999cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999cited by this paper
• Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

  1998cited by this paper
• Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.

  1998cited by this paper
• osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

  1998cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997cited by this paper
• Primer on the metabolic bone diseases and disorders of mineral metabolism

  1994cited by this paper
• Interrelationships between densitometric, geometric, and mechanical properties of rat femora: Inferences concerning mechanical regulation of bone modeling

  1993cited by this paper
• Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties

  1993cited by this paper
• Bone “mass” and the “mechanostat”: A proposal

  1987cited by this paper
• A Threshold Selection Method from Gray-Level Histograms

  1979cited by this paper
• Osteopetrosis cured by temporary parabiosis.

  1973cited by this paper
• In vivo osteocyte death.

  1960cited by this paper
• Printed in U.S.A. Copyright © 2001 by The Endocrine Society OPG and PTH-(1–34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats

  year unknowninfluential reference

• A variant form of receptor activator of nuclear factor-κB functions as an osteoprotegerin mimic in bone and cardiac development

  2025cites this paper
• RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes

  2023cites this paper
• Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

  2023cites this paper
• On the evolution and contemporary roles of bone remodeling

  2021cites this paper
• Placenta-Derived Osteoprotegerin Is Required for Glucose Homeostasis in Gestational Diabetes Mellitus

  2020cites this paper
• Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma

  2018influential citation
• Loss of Hdac3 in osteoprogenitors increases bone expression of osteoprotegerin, improving systemic insulin sensitivity

  2018cites this paper
• Comparative study of the effects of osteoprotegerin and testosterone on bone quality in male orchidectomised rats

  2018cites this paper
• One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.

  2017cites this paper
• Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study

  2017cites this paper
• Secondary osteoporosis in collagen-induced arthritis rats

  2016cites this paper
• The Dmp1‐SOST Transgene Interacts With and Downregulates the Dmp1‐Cre Transgene and the RosaNotch Allele

  2016cites this paper
• Canonical Notch activation in osteocytes causes osteopetrosis.

  2016cites this paper
• In Vivo siRNA Delivery Using JC Virus-like Particles Decreases the Expression of RANKL in Rats

  2016cites this paper
• Role of Polymer Architecture on the Activity of Polymer-Protein Conjugates for the Treatment of Accelerated Bone Loss Disorders.

  2015cites this paper
• 1 1 2 3 CANONICAL NOTCH ACTIVATION IN OSTEOCYTES CAUSES OSTEOPETROSIS 4 5 6 7 8

  2015cites this paper
• Effects of Denosumab, Alendronate, or Denosumab Following Alendronate on Bone Turnover, Calcium Homeostasis, Bone Mass and Bone Strength in Ovariectomized Cynomolgus Monkeys

  2015cites this paper
• [Sclerostin: a new biomarker of interest in nephrology].

  2015cites this paper
• Elevated serum osteoprotegerin levels in women: friend or foe?

  2015cites this paper
• Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway.

  2015cites this paper
• Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases

  2014cites this paper
• RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease

  2014cites this paper
• Notch Signaling in Osteocytes Differentially Regulates Cancellous and Cortical Bone Remodeling*

  2013cites this paper
• Emerging therapies for the treatment of osteoporosis

  2013cites this paper
• Osteoblast lineage-specific effects of notch activation in the skeleton.

  2013cites this paper
• Establishment of OPG Transgenic Mice and the Effect of OPG on Bone Microarchitecture

  2013cites this paper
• Inorganic polyphosphates: biologically active biopolymers for biomedical applications.

  2013cites this paper
• Assessment of Bone Mass and Microarchitecture in Rodents

  2013cites this paper
• Regulates Cancellous and Cortical Bone Notch Signaling in Osteocytes Differentially Molecular Bases of Disease :

  2013cites this paper
• Zinc Upregulates the Expression of Osteoprotegerin in Mouse Osteoblasts MC3T3-E1 Through PKC/MAPK Pathways

  2012cites this paper
• Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice.

  2012cites this paper
• The role of cytokines and the suppressors of cytokine signalling (SOCS) in human osteoblastic cell survival and bone remodelling

  2012cites this paper
• Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta

  2012cites this paper
• Bone Metabolism in Patients with Primary Hyperparathyroidism Before and After Surgery

  2012cites this paper
• Die Wirkung der antiresorptiven Therapie am Knochen

  2012influential citation
• Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

  2012cites this paper
• Cortical bone status is associated with serum osteoprotegerin concentration in men: the STRAMBO study.

  2011cites this paper
• Overexpression of osteoprotegerin promotes preosteoblast differentiation to mature osteoblasts.

  2011cites this paper
• Osteoporosetherapie durch monoklonale Antikörper - Neue klinische Daten - Les anticorps monoclonaux dans le traitement de losteoporose - de nouvelles donnees cliniques

  2011influential citation
• Der RANK-Ligand-Antikörper Denosumab als Beispiel der biotechnologischen Medikamentenentwicklung

  2011cites this paper
• Do RANKL inhibitors (denosumab) affect inflammation and immunity?

  2011cites this paper
• Denosumab and bisphosphonates: different mechanisms of action and effects.

  2011cites this paper
• Knochenfestigkeit und RANKL-Blockade - Neue präklinische Daten

  2010influential citation
• Guidelines for assessment of bone microstructure in rodents using micro–computed tomography

  2010cites this paper
• Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women.

  2010cites this paper
• Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone?

  2010cites this paper
• Clinical and basic research papers – October 2009

  2009cites this paper
• Progress in Osteoporosis

  2008cites this paper